Replies to post #233055 on Biotech Values

[DewDiligence]

PCVX delays IND filing for VAX-24:

https://finance.yahoo.com/news/vaxcyte-reports-fourth-quarter-full-201000080.html

“While our team has completed several additional key steps to support the IND application submission for VAX-24, in light of the combination of ongoing work to manufacture the 24 conjugated drug substances, capacity constraints at our contract manufacturing organization and, to a lesser degree, the impact of the COVID-19 pandemic, we are changing the expected timing of our VAX-24 IND application submission to between January and June 2022.”

The prior guidance for the IND filing had been 2H21. With the IND filing now expected in 1H22, the guidance for reporting phase-1/2 top-line data is “between late 2022 and early 2023.”